Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 113Urinary Bladder Neoplasms 56Carcinoma, Non-Small-Cell Lung 52Cholangiocarcinoma 33Biliary Tract Neoplasms 32Neoplasm Metastasis 30Ovarian Neoplasms 27Lymphoma, Large B-Cell, Diffuse 26Breast Neoplasms 25Lung Neoplasms 24Neoplasms 23Carcinoma, Transitional Cell 23Triple Negative Breast Neoplasms 22Nasopharyngeal Carcinoma 21Colorectal Neoplasms 20Recurrence 17Non-Muscle Invasive Bladder Neoplasms 16Gallbladder Neoplasms 15Fallopian Tube Neoplasms 15Sarcoma 13Bile Duct Neoplasms 11Parkinson Disease 4, Autosomal Dominant Lewy Body 10Hodgkin Disease 10Lymphoma 9Uterine Cervical Neoplasms 8Adenocarcinoma 8Stomach Neoplasms 7Lymphoma, Non-Hodgkin 7Endometrial Neoplasms 7Nasopharyngeal Neoplasms 6

Interventions

Gemcitabine 2130-nm albumin-bound paclitaxel 2Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Locally Advanced Pancreatic Cancer × Gemcitabine × 1 year × Clear all
NCT03652428 2026-05-06

Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)

University of Maryland, Baltimore

Phase 1/2 Recruiting
24 enrolled
Gastrointestinal

Locally Advanced Pancreatic Cancer

NCT03257033 2025-11-14

TIGeR-PaC

RenovoRx

Phase 3 Recruiting
190 enrolled
Gastrointestinal

Locally Advanced Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡